Science and Research

M23-385

A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors.

Study details
Study-ID: NCT05599984, 2023-504598-18
DZL Disease Area: LC
Study Type: Interventional
DZL Role: DZL recruiting center
Funding: Externally - industry
DZL Participating Sites: CPC-M
Start Date: 05.12.2022
Completion Date: 17.05.2027
Status: Recruiting
Link to Study


chevron-down